Movement Alert｜GRAIL, Inc. Intraday Rise 5.12% in Regular Trading, FDA panel support and UBS target hike bolster sentiment

Market Focus10-27

On October 27, GRAIL, Inc. rose 5.12% in Regular Trading, trading at $147.4 per share, with turnover of $23.2558 million.

The move followed continued positive read-through from Galleri after the FDA advisory committee recommended the multi-cancer early detection test, alongside UBS raising its price target to $175 from $105 while maintaining a buy rating.

Committee voting showed unanimous support on safety at 10 to 0, narrower support on efficacy at 6 to 4, and a 7 to 2 vote with one abstention on the benefit-risk profile for use in adults aged 50 years or older. Recent market attention has shifted more toward product positioning and labeling than core safety concerns, reinforcing expectations around regulatory progress and commercialization potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment